Abstract
Rationale A major part of diagnosis and follow-up in patients with multiple sclerosis is based on MRI evaluations. As T1-hypointense lesions represent neural destruction or axonal loss and anticipate irreversible disability in the patients, evaluation of the effects of Disease-modifying therapies (DMTs) on the volume of black holes seems necessary.
Objectives To evaluate the effects of FDA approved disease-modifying therapies (DMTs) on T1 hypointense lesions (Black Holes) volume in patients with multiple sclerosis (MS)
Data sources We will search MEDLINE (through Ovid), Embase, and CENTRAL. We won’t consider any timeframe, language, or geographical restrictions.
Methods We will include only randomized controlled trials (RCTs) that have evaluated the effects of DMTs on black holes mean volume in adult patients diagnosed with any phenotype of multiple sclerosis (MS) in comparison to the placebo, routine care, or no treatment regimen. We will assess the risk of bias in the primary studies using the Revised Cochrane risk-of-bias tool for randomized trials (RoB2). Data will be synthesized based on the random-effects model and results will be plotted on a forest plot. Heterogeneity will be assessed using I2 statistics. If feasible, we will also perform subgroup analyses for each DMT.
Funding This study is not funded.
Registration PROSPERO submission ID: 262883.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is not funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
mrfatahi93{at}gmail.com, sahraian1350{at}yahoo.com, a-azimi{at}sina.tums.ac.ir, maryam.sadeghi1993{at}gmail.com, M.storbati{at}yahoo.com
Data Availability
Important protocol amendments post registration will be recorded and included in dissemination.
